Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.
Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX.
JCO Oncol Pract. 2021 May;17(5):265-271. doi: 10.1200/OP.21.00001.
Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that a prompt improvement of Black Americans participation is warranted.
美国黑人参与癌症临床试验的比例低是一个既定的困境。许多因素导致了目前的困境，其中种族主义是根本原因。在这里，我们讨论了一些当前的挑战和提出的解决方案，以帮助增加美国黑人参与癌症临床试验的人数。我们建议实施最不可接受的特定种族百分比作为新的标准，注册临床试验需要在批准癌症药物之前通过这个标准。临床试验将继续为癌症治疗的未来绘制蓝图，我们相信有必要迅速提高美国黑人的参与度。
